14 results found.

Atopic Dermatitis Clinical Trial using MK-8226; Placebo

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase Ib Randomized, Double-Blinded, Placebo-Controlled Multiple Rising Dose Clinical Trial to Evaluate the Safety, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous MK-8226 in Patients With Moderate to Severe Atopic Dermatitis.
MK-8226; Placebo

Mild to Moderate Atopic Dermatitis Clinical Trial using SB011, 2 % (Water/Oil/Water) emulsion of hgd40; Multiple W/O/W formulation, active ingredient-free vehicle

Sterna Biologicals GmbH & Co. KG - Recruiting 18 years to 60 years.
- A Phase IIa, Single-centre, Randomised, Vehicle Controlled, Double-blind Trial for Assessment of Efficacy, Safety and Tolerability of the Topical Formulation SB011 Containing a Human GATA-3 Specific DNAzyme and of Systemic Absorption of hgd40 Following Application to Lesional Skin in Patients With Atopic Eczema.
SB011, 2 % (Water/Oil/Water) emulsion of hgd40; Multiple W/O/W formulation, active ingredient-free vehicle

Dermatitis, Atopic, or Eczema, Atopic Clinical Trial using Tofacitinib ointment 20mg/g; Placebo ointment (Vehicle)

Pfizer - Recruiting 18 years to 50 years.
- A Phase 2a, Multi-Site, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study Of The Pilot Efficacy, Safety, Tolerability, And Pharmacokinetics Of 2% Tofacitinib Ointment In Subjects With Mild To Moderate Atopic Dermatitis.
Tofacitinib ointment 20mg/g; Placebo ointment (Vehicle)

Atopic Dermatitis, Netheron's Syndrome, Piebaldism, Hyper IgE Syn Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 80 years.
- Natural History of Atopic Dermatitis and Other Genetic/Congenital Diseases Associated With Allergic Inflammation.

Anakinra, Kineret, Atopic Dermatitis, Eczema, or Allergic Disease Clinical Trial using Anakinra

National Institutes of Health Clinical Center (CC) - Recruiting 10 years to 30 years.
- A Pilot Study Using Anakinra/Kineret for the Treatment of Patients With Severe Atopic Dermatitis.
Anakinra

Dermatitis, Atopic Clinical Trial using Ustekinumab; Placebo; Concomitant topical medications for atopic dermatitis

Janssen Pharmaceutical K.K. - Recruiting 20 years to 65 years.
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study of Ustekinumab in Adult Japanese Subjects With Severe Atopic Dermatitis.
Ustekinumab; Placebo; Concomitant topical medications for atopic dermatitis

Atopic Dermatitis Clinical Trial using FURESTEM-AD Inj.

Kang Stem Holdings Co., Ltd. - Recruiting 20 years to 60 years.
- Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis.
FURESTEM-AD Inj.

Dermatitis, Atopic Clinical Trial using Phoenix II (BAY81-2996); Phoenix I (BAY81-2996)

Bayer - Recruiting 18 years to 60 years.
- An Investigator-blinded, Randomized, Monocentre, 3-arm, Pilot Trial to Compare the Efficacy and Safety of Two Topical Medical Devices in Patients With Mild to Moderate Atopic Dermatitis in an Intra-individual Comparison With Untreated Skin.
Phoenix II (BAY81-2996); Phoenix I (BAY81-2996)

Atopic Dermatitis Clinical Trial using ILV-094; Placebo Comparator

Rockefeller University - Recruiting 18 years to 75 years.
- Phase II Study to Determine the Safety, Tolerability, Pharmacodynamics and Clinical Efficacy of ILV-094 (an IL-22 Antibody) in Subjects With Atopic Dermatitis (AD).
ILV-094; Placebo Comparator

Atopic Dermatitis (AD) Clinical Trial using dupilumab; placebo

Regeneron Pharmaceuticals - Recruiting 18 years or older.
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Investigating the Efficacy, Safety, Serum Concentration and Biomarker Profile of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis.
dupilumab; placebo

Atopic Dermatitis Clinical Trial using OC000459

Atopix Therapeutics, Ltd. - Recruiting 18 years to 40 years.
- A Study of the Effect of OC000459 on Signs and Symptoms in Subjects With Moderate to Severe Atopic Dermatitis: A Randomised Double Blind Placebo Controlled Parallel Group Study.
OC000459

Atopic Dermatitis Clinical Trial using LEO 39652 cream; cream vehicle

LEO Pharma - Recruiting 18 years to 65 years.
- A Phase I, First-in-Human, Vehicle Controlled, Single Ascending Dose Trial Evaluating the Safety, Tolerability and Pharmacokinetics in Male Subjects With AD and in Healthy Male Subjects of Cutaneous Application of LEO 39652 Cream.
LEO 39652 cream; cream vehicle

Eczema, Hand Eczema, or Atopic Dermatitis Clinical Trial using CLn BodyWash; Cetaphil Daily Facial Cleanser

TopMD Skin Care, Inc. - Recruiting 18 years or older.
- A Double-Blind Pilot Study To Assess The Feasibility of a Larger Study to Assess The Efficacy of A Novel Gel Wash Cleanser Formulated With Sodium Hypochlorite To Reduce Skin Fauna In Patients With Chronic Hand Dermatitis/Atopic Dermatitis..
CLn BodyWash; Cetaphil Daily Facial Cleanser

Moderate to Severe Atopic Dermatitis Clinical Trial using Dilute bleach baths; Water

University of Texas Southwestern Medical Center - Recruiting 2 years to 17 years.
- A Randomized, Controlled, Evaluator-blinded Study to Evaluate the Efficacy of Dilute Bleach Baths on Skin Disease Control in Pediatric Patients With Atopic Dermatitis.
Dilute bleach baths; Water